LinkedIn

Paul Bolno, MD, MBA

President and Chief Executive Officer

Dr. Paul Bolno has served as President and CEO of Wave since 2013 and oversaw the company’s initial public offering in 2015. During his tenure as President and CEO, Paul has grown Wave into a fully integrated clinical-stage genetic medicines company, overseen the development of the company’s proprietary stereopure oligonucleotide discovery and drug development platform, and built a broad pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities.

In addition to his current role at Wave, Paul is on the Board of Directors for SQZ Biotech and serves as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom.

Prior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK). He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Paul joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a healthcare private equity firm.

Paul earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.